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A favourable treatment outcome is dependent on the efficacy 
of the treatment as well as its early detection, rendering imaging 
technologies crucial. Magnetic resonance imaging (MRI) is 
amongst the most widely used imaging techniques, and a number 
of gadolinium paramagnetic complexes are available as contrast 
agents.1 Nonetheless, their side effects and nephrotoxicity have 
raised considerable concerns.2 Using 19F atoms as MRI contrast 
agents offers significant advantages: its 100% natural abundance, 
its absence in biological media which avoids confusion with 
other possible signal sources, and its large gyromagnetic ratio 
which ensures good sensitivity.3-4 
An important consideration in the design of 19F MRI agents is 
the need for a single NMR/MRI signal, hence the 19F atoms must 
be magnetically equivalent. The design of 19F-based contrast 
agents therefore often includes the use of trifluoromethyl groups. 
Grafting as many CF3 groups as possible on a polymeric scaffold, 
possibly dendrimeric with pseudo-equivalent 19F atoms, is one of 
the preferred options.5 Small non-toxic molecules used at higher 
concentrations, such as perfluoro-18-crown-6-ether6a and 
Perfecta which has 36 equivalent 19F atoms, have also been 
developed.6b The flexibility of the trifluoromethyl group has 
proved to play a role in ensuring an intense MRI signal.7 On the 
other hand, cyclophosphazenes have often been used as 
dendrimeric cores or as scaffolds for polyfunctionalization, and 
are biocompatible.8-9 The convenient insertion of substituents by 
nucleophilic substitution, usually high-yielding, is another 
advantage of this molecular basis. 
All these parameters have been taken into account to design 
19F MRI contrast agents using a cyclotriphosphazene scaffold. A 
commercially available benzyl alcohol bearing two equivalent 
trifluoromethyl moieties was selected, relying on the flexibility 
afforded by the benzylic methylene compared to a phenol that 
would be, conversely, more reactive. The chlorine nucleophilic 
substitution reaction performed in tetrahydrofuran using sodium 
hydride as the base gave 1 in excellent yield (Scheme 1) and 
chromatographic purification was facile thanks to the difference 
in polarity of 1 and the benzylic alcohol. Reproduction of the 
reaction and simply washing the crude precipitate also allowed 
the isolation of 1 with a satisfactory purity (>90%), which 
represents a good starting point for future up-scaled synthesis. 
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A cyclotriphosphazene substituted with six 3,5-bis(trifluoromethyl) benzyloxy units was 
designed as a novel 19F MRI contrast agent. The resulting molecule has 36 magnetically 
equivalent fluorine atoms and exhibited suitable MRI properties with high imaging sensitivity, 
confirming the proof-of-concept as a convenient scaffold for the production of new 19F MRI 
contrasts agents. 
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Scheme 1. Preparation of 1. 
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Exhaustive NMR characterization of 1 was performed (Fig. 1 
and ESI). All peaks in the 1H decoupled 13C NMR spectrum were 
assigned using HSQC experiments (ESI, Fig. S5), which was 
particularly useful to discriminate CHa and CHb2 (Fig. 1). The 1J 
coupling constant between the carbon and fluorine atoms of the 
CF3 groups had a value of 272.7 Hz, while the 2J coupling (C-
CF3) had a value of 33.7 Hz. 19F NMR spectroscopy confirmed 
the magnetic equivalence of the 36 19F atoms. Similarly, and as 
can be also expected, all 31P atoms were equivalent. 
Single crystals of compound 1 were obtained from the slow 
diffusion of a CH2Cl2/hexane mixture and the solid-state structure 
was solved and refined using single-crystal X-ray diffraction data 
(Fig. 2). Compound 1 crystallizes in the orthorhombic system 
and the non-centrosymmetrical P21212 space group (Flack 
parameter refined to the value 0.11(17)) was retained. Data 
collection conditions as well as refinement results are presented 
in the ESI (Table S1). Selected bond lengths and angles are 
reported in Tables S2 and S3, respectively. The P-N (from 
1.574(4) Å to 1.585(4) Å) and P-O (from 1.569(3) Å) to 1.580(3) 
Å) bond lengths are in good agreement with the previous 
structure of this type of cyclotriphosphazene, as well as the 
P−N−P (122.7(3)°) and N−P−N (117.2(2)° and (118.2(3°) 
angles.10-11 All lengths for C-O bonds (from 1.450(5) Å to 
1.460(6) Å) involving the first C atom of the phenyl ring and the 
O atom attached to the P atom of the cyclotriphosphazene ring 
are in the normal ranges. The 3-D network of 1 is built from C-
F…F-C interactions between neighboring molecules and lead to 
planes perpendicular to the [100] direction of the unit-cell (Fig. 
2). 
To test the 19F MRI properties of compound 1, 19F MRI 
measurements of solutions at varying concentrations of 1 in 
CHCl3 were conducted at a field strength of 9.4 T. As illustrated 
in Figure 3a, 1H RARE (rapid acquisition with relaxation 
enhancement) images are displayed (top) to illustrate the location 
of the NMR tubes within the resonator. All of the samples with 
19F concentrations ranging from 3 to 100 mM could be detected 
successfully by 19F MRI as shown in the 1H MRI, indicating the  
 
 
Figure 1. 1H (a), 13C (b), 31P (c) and 19F (d) NMR spectra of 1 in 
CDCl3. 
Figure 2. Top: Crystal structure of 1. Hydrogen atoms have been 
omitted for clarity. Bottom: Packing views of compound 1 along 
the (b,c)-plane. F…F interaction are represented with light-blue 
dashed lines. 
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high sensitivity of compound 1 as a 19F MRI contrast agent. 
Moreover, the 19F MRI signal-noise-ratio (SNR) was calculated 
for illustrating the quantitative nature of the 19F MRI 
experiments. As shown in Figure 3b, a good linear relationship of 
19F MRI SNR to the concentration of sample 1 can be observed 
(R2 = 0.982). These observations all indicate that compound 1 is a 
promising quantitative 19F MRI contrast agent with high imaging 
sensitivity due to the numerous chemically equivalent fluorine 
atoms in one molecule (Scheme 1). In the meantime, the 19F 
NMR T1 and T2 relaxation times of 1 were monitored at these 
imaging conditions (Table S4). It is noteworthy that the T2/T1 
ratio is above 0.9 for compound 1 at all testing conditions, 
highlighting the good 19F MR imaging sensitivity.12 The 19F T1 of 
1 is significantly shorter than the majority of fluorinated small 
compounds, such as trifluoroethanol (TFE), under same 
conditions (~1500 vs. ~2400 ms).13 From a sensitivity point of 
view, a shorter T1 allows for a greater number of scans to be 
obtained in an equivalent time frame and thus better sensitivity. 
 
 
 
 
To conclude, these proof-of-concept experiments demonstrate 
for the first time that cyclophosphazene is an excellent scaffold 
for the construction of 19F MRI contrast agents. The next steps 
will be formulation studies, chosen to minimize the issues of 
entrapment and compartmentalisation, for in vitro then in vivo 
investigations. Improvement of the relaxation time by 
conjugation to metal complexes, which was previously proved14 
to considerably optimize the relaxation rate, will also be 
explored. 
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Figure 3. (a) 19F MRI images of solutions of 1 (CHCl3) at various 
concentrations. (b) Signal-to-noise ratio of 1 increases linearly 
with respect to concentration of 1. Field strength : 9.4 T. 
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• A cyclotriphosphazene substituted by six 3,5-
bis(trifluoromethyl) benzyloxy units has been 
prepared. 
• The fnal molecule bears 36 magnetically 
equivalent fluorine atoms. 
• Suitable MRI properties with high imaging 
sensitivity have been demonstrated 
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